Next week, Katana Labs will be represented at two important events bringing together innovators across biotech, biopharma, cancer research, translational oncology, and precision medicine: bio:cap in Berlin or EACR 2026 in Budapest.
We look forward to discussing how AI can advance our understanding of complex disease biology โ especially how spatial tissue context can reveal cell behavior, tumorโimmune interactions, niche organization, and molecular patterns that are critical for biomarker discovery and precision therapy development.
At Katana Labs, we are building Katana Edge, an AI-powered platform for spatial molecular profiling, spatial multiomics, and advanced tissue analysis. Our goal is to turn multidimensional data from scanned tissue samples into actionable insights that support biomarker discovery, translational research, and biopharma R&D.
Spatial biology is becoming a key technology for understanding cancer and other complex diseases โ and we believe AI will be essential to make these datasets scalable, reproducible, and truly useful for research and drug development.
If you are attending bio:cap in Berlin or EACR 2026 in Budapest and are working on spatial biology, cancer research, biomarker discovery, translational oncology, or AI in precision medicine, we would be happy to connect and exchange ideas.
